Relmada Therapeutics, Inc.
$6.33
-1.4%Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -4.4).
Valuation inputs: P/E -4.4, earnings yield N/A, momentum -1.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -66.3%, ROIC -67.5%).
Profitability stack: net margin 0.0%, ROE -66.3%, ROIC -67.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.0%, momentum -1.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Relmada Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Relmada Therapeutics, Inc. Fair Value Envelope
No Revenue Data
RLMD has not reported any revenue values in the available annual periods.
Relmada Therapeutics, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
RLMD has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
RLMD has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
RLMD has not reported any net profit margin values in the available annual periods.
Relmada Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Relmada Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Relmada Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that RLMD stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 9.00, with estimates ranging from a low of 8.00 to a high of 10.00.
The consensus 1-year price target stands at 9.00, with estimates ranging from a low of 8.00 to a high of 10.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Relmada Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.21M worth of RLMD shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
39.2K
161.36K
0
0.00
+161K
+$161K
6-9 Months
998.5K
2.20M
0
0.00
+2.2M
+$2.20M
9-12 Months
2.8M
1.85M
0
0.00
+1.9M
+$1.85M
Top Buyers
Shenouda Maged
Officer: Chief Financial Officer
$1.55M
Traversa Sergio
Director, Officer: Chief Executive Officer
$1.43M
Ence Chuck
Officer: Cao And Coo
$567K
Kelly Paul Edward
Director, Officer: Chief Operating Officer
$466K
Casamento Charles J
Director
$67K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.21M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
RLMD has not reported any dividend yield values in the available annual periods.
rlmd Dividend History
Learning Layer
Related Guides
Build conviction on RLMD by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.